Provention Bio Inc Stock Research

Market Summary

USD23.95+0.06

Market Closed

0.25%

PRVB Stock Price

PRVB RSI Chart

PRVB Valuation

Market Cap

2.1B

Price/Earnings (Trailing)

-19.65

Price/Sales (Trailing)

750.79

EV/EBITDA

-17.76

Price/Free Cashflow

-22.82

PRVB Price/Sales (Trailing)

PRVB Profitability

EBT Margin

-4075.33%

Return on Equity

-73.3%

Return on Assets

-54.72%

Free Cashflow Yield

-4.38%

PRVB Fundamentals

PRVB Revenue

Revenue (TTM)

2.8M

Revenue Y/Y

Revenue Q/Q

1.34%

PRVB Earnings

Earnings (TTM)

-106.1M

Earnings Y/Y

-5.96%

Earnings Q/Q

3.55%

Price Action

52 Week Range

3.1924.23

(Low)(High)

Last 7 days

-0.2%

Last 30 days

192.8%

Last 90 days

144.6%

Trailing 12 Months

208.2%

PRVB Financial Health

Current Ratio

7.58

PRVB Investor Care

Shares Dilution (1Y)

37.36%

Peers (Alternatives to Provention Bio)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	402.9B	94.9B	-1.71%	-11.01%	22.45	4.24	1.25%	-14.07%
LLY	301.4B	28.5B	4.03%	16.86%	48.26	10.56	0.79%	11.88%
MRK	272.8B	59.3B	-2.02%	35.43%	17.88	4.63	21.72%	11.27%
PFE	225.5B	100.3B	-3.66%	-21.92%	7.19	2.25	23.43%	42.74%
BMY	144.7B	46.2B	-3.01%	-5.06%	22.87	3.14	-0.49%	-9.54%
MID-CAP
PRGO	4.6B	4.5B	-5.71%	-9.25%	-32.73	1.03	7.56%	-104.06%
SMALL-CAP
PRVB	2.1B	2.8M	192.79%	208.24%	-19.65	750.79	245.83%	12.43%
PCRX	1.8B	666.8M	-2.27%	-47.61%	115.68	2.76	23.14%	-62.10%
TLRY	1.6B	602.5M	-7.75%	-62.41%	-2.78	2.67	18.18%	-18.59%
CGC	913.9M	478.9M	-19.31%	-78.37%	-0.29	1.91	-31.50%	-634.70%
AERI	753.2M	213.9M	0.39%	48.49%	-20.6	3.52	105.41%	78.04%
CRON	745.9M	114.5M	-6.67%	-53.88%	-4.42	6.52	27.90%	57.40%
TBPH	703.8M	51.3M	9.32%	11.12%	0.81	13.71	-7.17%	537.32%
NGM	322.6M	55.3M	-14.16%	-75.24%	-1.98	5.83	-29.00%	-35.18%

Financials for Provention Bio

Income Statement (Last 12 Months)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Revenue	2.1%	2,777,000	2,721,000	2,006,000	1,395,000	803,000
Operating Expenses	1.8%	116,651,000	114,572,000	114,166,000	116,973,000	123,016,000
S&GA Expenses	7.3%	51,132,000	47,668,000	46,871,000	47,346,000	48,056,000
R&D Expenses	-2.1%	65,519,000	66,904,000	67,295,000	69,627,000	74,960,000
EBITDA	-0.1%	-111,628,000	-111,570,000	-115,032,000	-	-
EBITDA Margin	27.7%	-40.20	-55.62	-82.46	-	-
Earnings Before Taxes	-1.4%	-113,172,000	-111,561,000	-112,016,000	-115,432,000	-122,180,000
EBT Margin	-0.2%	-40.75	-40.67	-55.84	-82.75	-
Interest Expenses	Infinity%	1,020,000	0.00	-	-	-
Net Income	-1.5%	-106,116,000	-104,505,000	-103,960,000	-114,432,000	-121,180,000
Net Income Margin	-0.3%	-38.21	-38.10	-51.82	-82.03	-
Free Cahsflow	1.1%	-91,366,000	-92,342,000	-94,639,000	-96,346,000	-

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Assets	85.8%	194	104	122	136	158
Current Assets	110.9%	190	90.00	92.00	101	155
Cash Equivalents	76.8%	102	58.00	75.00	78.00	139
Net PPE	2.6%	2.00	2.00	2.00	2.00	2.00
Liabilities	91.4%	49.00	26.00	28.00	25.00	24.00
Current Liabilities	-0.1%	25.00	25.00	27.00	23.00	21.00
LT Debt, Non Current	Infinity%	23.00	-	-	-	-
Shareholder's Equity	84.0%	145	79.00	94.00	111	134
Retained Earnings	-8.4%	-372	-343	-314	-292	-266
Additional Paid-In Capital	22.4%	518	423	409	403	400
Accumulated Depreciation	24.4%	1.00	1.00	0.00	0.00	-
Shares Outstanding	31.1%	87.00	66.00	64.00	63.00	63.00

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Cashflow From Operations	1.5%	-90.89	-92.27	-93.93	-95.38	-96.56
Share Based Compensation	1.4%	12.00	12.00	12.00	12.00	17.00
Cashflow From Investing	-383.7%	-74.55	-15.41	-13.67	-31.10	15.00
Cashflow From Financing	832.0%	128	14.00	2.00	102	103

Risks for PRVB

What is the probability of a big loss on PRVB?

95.5%

Probability that Provention Bio stock will be more than 20% underwater in next one year

94.7%

Probability that Provention Bio stock will be more than 30% underwater in next one year.

91.9%

Probability that Provention Bio stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does PRVB drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Provention Bio was unfortunately bought at previous high price.

Drawdowns

Returns for PRVB

Cumulative Returns on PRVB

42.1%

3-Year Cumulative Returns

Which funds bought or sold PRVB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-23	MetLife Investment Management, LLC	unchanged	-	186,859	325,387	-%
2023-03-10	VICTORY CAPITAL MANAGEMENT INC	new	-	524,695	524,695	-%
2023-03-06	Rockefeller Capital Management L.P.	unchanged	-	18,000	31,000	-%
2023-02-28	Voya Investment Management LLC	unchanged	-	149,176	259,176	-%
2023-02-27	Parallax Volatility Advisers, L.P.	added	21.88	134,701	207,701	-%
2023-02-21	MACQUARIE GROUP LTD	unchanged	-	425,000	740,000	-%
2023-02-15	JANE STREET GROUP, LLC	added	2,174	2,713,710	2,765,710	-%
2023-02-15	ALLIANCEBERNSTEIN L.P.	unchanged	-	556,212	968,212	-%
2023-02-15	Steward Partners Investment Advisory, LLC	reduced	-85.78	-1,324	676	-%
2023-02-15	Metropolitan Life Insurance Co/NY	unchanged	-	21,936	37,936	-%

Latest Funds Activity

Are funds buying PRVB calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own PRVB

No. of Funds

Provention Bio News

Schedule 13G FIlings of Provention Bio

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 21, 2023	adage capital partners gp, l.l.c.	6.01%	5,398,825	SC 13G
Feb 14, 2023	sessa capital (master), l.p.	19.99%	18,066,613	SC 13G/A
Feb 14, 2023	venrock healthcare capital partners ii, l.p.	1.3%	1,118,653	SC 13G/A
Feb 09, 2023	adage capital partners gp, l.l.c.	2.89%	2,519,257	SC 13G/A
Feb 01, 2023	blackrock inc.	6.4%	5,579,604	SC 13G/A
Aug 26, 2022	adage capital partners gp, l.l.c.	6.50%	5,300,000	SC 13G
Jul 11, 2022	sessa capital (master), l.p.	19.99%	15,610,170	SC 13G/A
Feb 14, 2022	perceptive advisors llc	1.5%	948,481	SC 13G/A
Feb 14, 2022	sessa capital (master), l.p.	9.3%	5,895,525	SC 13G
Feb 03, 2022	blackrock inc.	7.1%	4,483,925	SC 13G/A

PRVB Fair Value

Provention Bio fair value in different scenarios

The table shows the Fair Value estimates for Provention Bio for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.

Fair Value	Very Pessimistic	Pessimistic	Base Case	Optimistic	Very Optimistic
Very Low Inflation	0.41 -98.29%	0.41 -98.29%	0.43 -98.20%	0.47 -98.04%	0.54 -97.75%
Current Inflation	0.41 -98.29%	0.41 -98.29%	0.42 -98.25%	0.46 -98.08%	0.52 -97.83%
Very High Inflation	0.41 -98.29%	0.41 -98.29%	0.42 -98.25%	0.45 -98.12%	0.50 -97.91%

Historical Provention Bio Fair Value Estimates

Very Pessimistic Case

Pessimistic Case

Fair Value

Optimistic Case

Very Optimistic Case

Closing Stock Price

Recent SEC filings of Provention Bio

View All Filings

Date Filed	Form Type	Document
Mar 24, 2023	8-K/A	Current Report
Mar 24, 2023	SC 14D9	SC 14D9
Mar 24, 2023	SC TO-T	SC TO-T
Mar 17, 2023	SC TO-C	SC TO-C
Mar 13, 2023	8-K	Current Report
Mar 13, 2023	SC14D9C	SC14D9C
Mar 13, 2023	SC TO-C	SC TO-C
Feb 21, 2023	SC 13G	Major Ownership Report
Feb 16, 2023	8-K/A	Current Report
Feb 14, 2023	4	Insider Trading

Latest Insider Trading transactions for PRVB

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-02-13	Leon Francisco	acquired	64,962	2.5	25,985	chief scientific officer
2023-02-13	Palmer Ashleigh	acquired	64,587	2.5	25,835	director and ceo
2023-02-13	Palmer Ashleigh	sold	-259,448	10.0425	-25,835	director and ceo
2023-02-13	Leon Francisco	sold	-260,944	10.0421	-25,985	chief scientific officer
2023-02-10	Palmer Ashleigh	acquired	125,000	2.5	50,000	director and ceo
2023-02-10	Palmer Ashleigh	sold	-505,555	10.1111	-50,000	director and ceo
2023-02-10	Leon Francisco	acquired	125,000	2.5	50,000	chief scientific officer
2023-02-10	Leon Francisco	sold	-505,605	10.1121	-50,000	chief scientific officer
2023-02-10	Hoitt Jason	sold	-45,005	10.0012	-4,500	chief commercial officer
2023-01-18	Leon Francisco	acquired	60,037	2.5	24,015	chief scientific officer

About Provention Bio

Ashleigh W. Palmer

www.proventionbio.com

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.

PRVB Income Statement

2022-09-30

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue from Contract with Customer [Abstract]
Collaboration revenue	$ 756	$ 678	$ 2,082	$ 678
Operating expenses:
Research and development	16,339	17,724	50,271	54,379
General and administrative	13,495	10,031	39,803	36,017
Total operating expenses	29,834	27,755	90,074	90,396
Loss from operations	(29,078)	(27,077)	(87,992)	(89,718)
Interest income, net	700	55	903	114
Interest expense	(255)		(255)
Loss before income tax benefit	(28,633)	(27,022)	(87,344)	(89,604)
Income tax benefit			7,056	1,000
Net loss	$ (28,633)	$ (27,022)	$ (80,288)	$ (88,604)
Net loss per common share, basic and diluted	$ (0.34)	$ (0.43)	$ (1.14)	$ (1.41)
Weighted average common shares outstanding, basic and diluted	83,119	63,375	70,484	63,008
Other comprehensive (loss) income:
Unrealized (loss) gain on marketable securities	$ (45)	$ (15)	$ (747)	$ 12
Total comprehensive loss	$ (28,678)	$ (27,037)	$ (81,035)	$ (88,592)

PRVB Balance Sheet

2022-09-30

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 102,382	$ 78,190
Marketable securities	83,139	16,921
Prepaid expenses and other current assets	4,913	5,985
Total current assets	190,434	101,096
Non-current assets:
Marketable securities	1,007	32,021
Fixed assets, net	2,016	2,011
Operating lease right-of-use assets	336	373
Other assets	120	120
Total non-current assets	3,479	34,525
Total assets	193,913	135,621
Current liabilities:
Accounts payable	3,791	3,546
Accrued expenses and other current liabilities	13,552	13,646
Deferred revenue	7,775	5,599
Total current liabilities	25,118	22,791
Debt, long-term	23,298
Deferred revenue, net of current portion	248	1,506
Operating lease liabilities, long-term	480	590
Total liabilities	49,144	24,887
Commitments and Contingencies (Note 6)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 25,000,000 shares authorized; no shares issued or outstanding at September 30, 2022 and December 31, 2021
Common stock, $0.0001 par value; 150,000,000 shares authorized; 87,054,053 shares issued and outstanding at September 30, 2022; 63,374,738 shares issued and outstanding at December 31, 2021	9	6
Additional paid-in capital	518,008	402,941
Accumulated other comprehensive loss	(886)	(139)
Accumulated deficit	(372,362)	(292,074)
Total stockholders’ equity	144,769	110,734
Total liabilities and stockholders’ equity	$ 193,913	$ 135,621